| | |||||
| lung cancer | |||||
| 新闻 | |||||
| Camrelizumab/Apatinib Plus Chemotherapy May Show Promise in ES-SCLC Partial responses (PRs) occurred in 66.7% of patients, and 30.6% experienced stable disease. Read more. Small Cell Lung Cancer (SCLC). Advertisement.
| |||||
| 查看更多结果 | 修改此快讯 | |||||
| 您收到此电子邮件是因为您订阅了Google快讯。 |
以RSS Feed的形式接收此快讯 |
| 发送反馈 |
No comments:
Post a Comment